BITS Faculty Publications

Permanent URI for this communityhttp://localhost:4000/handle/123456789/1867

Browse

Search Results

Now showing 1 - 3 of 3
  • Item
    The multifaceted role of lncRNA MEG3 in kidney disease: a focus on mechanisms, therapeutic and diagnostic potential
    (Elsevier, 2025-09) Majumder, Syamantak; Gaikwad, Anil Bhanudas
    Kidney disease represents a global health challenge, affecting millions of people and contributing to significant morbidity and mortality. Long noncoding RNAs are potentially emerging as regulators in cellular processes and are involved in pathophysiological alterations in kidney disease. Among these, MEG3 has gained attention for its diverse regulatory roles in fibrosis, apoptosis and inflammation. MEG3 dysregulation has been implicated in conditions like chronic kidney disease, acute kidney injury, diabetic kidney disease and renal cell carcinoma. However, its involvement in endoplasmic reticulum (ER) stress and autophagy, crosstalk in kidney disease, is poorly understood. Hence, this review aims to highlight the role of MEG3 as a therapeutic and diagnostic viewpoint in kidney disease and its regulatory mechanism in ER stress and autophagy.
  • Item
    ULK1 as a therapeutic target in kidney diseases: Current perspective
    (Taylor & Francis, 2024-11) Gaikwad, Anil Bhanudas
    Globally, ~850 million people are affected by different kidney diseases. The pathogenesis of kidney diseases is intricate, where autophagy is crucial for maintaining kidney homeostasis. Iteliminates damaged organelles, thus reducing renal lesions and allowing tissue regeneration. Therefore, targeting various autophagy proteins, e.g. Unc–51–like autophagy-activating kinase 1 (ULK1), is emerging as potential therapeutic strategy against kidney disease.
  • Item
    Management of inflammaging in kidney diseases: focusing on the current investigational drugs
    (Taylor & Francis, 2024-10) Gaikwad, Anil Bhanudas
    To improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting specific pathways involved in inflammaging with potential drugs.